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Induction of the Epstein–Barr virus lytic cycle in latently infected B cells requires the expression of the immediate-early
lytic gene BZLF1. We have previously identified several cis-elements within the BZLF1 promoter that are required for
induction by known inducers of the lytic cycle [E. Flemington and S. H. Speck (1990) J. Virol. 64, 1217–1226]. These include
four elements termed the ZI domains (ZIA, ZIB, ZIC, and ZID) that share extensive homology and that have recently been
shown to bind several cellular transcription factors [A. M. Borras, J. L. Strominger, and S. H. Speck (1996) J. Virol. 70, 3894–
3901]. Here Sp1 and Sp3 are identified as the cellular factors present in crude B cell nuclear extract preparations that bind
to the ZIC domain. In addition, three of the four complexes observed in electrophoretic mobility shift analyses employing
probes containing either the ZIA or the ZID domains also represent Sp1 or Sp3 binding. Binding of Sp1 and Sp3 to the ZI
domains was shown to be significantly weaker than binding of these factors to a consensus Sp1 site. A heterologous
promoter construct containing three repeats of a consensus Sp1 site, cloned upstream of a single copy of the ZII (CREB/
AP1) element from the BZLF1 promoter linked to the b-globin TATA box, exhibited phorbol ester inducibility. The latter
observation was consistent with the functional behavior exhibited by a heterologous promoter construct containing multiple
copies of the ZIC domain liked to the ZII element. However, the basal activity of the heterologous promoter construct driven
by the consensus Sp1 sites was ca. 10-fold higher than that of the heterologous reporter construct containing multimerized
ZIC sites. Thus, the low affinity of Sp1 binding to the ZI domains may contribute to the low-level basal activity of the BZLF1
promoter. q 1997 Academic Press
INTRODUCTION Luka et al., 1979; Takada and Ono, 1989; Tovey et al.,
1978; zur Hausen et al., 1978).
Epstein–Barr virus (EBV) is a human gammaherpesvi-
Activation of the viral lytic cascade by crosslinkingrus that predominantly establishes a latent infection in
surface immunoglobulin results in the initial expressionB lymphocytes. Propagation of EBV from host to host is
of two viral genes, BZLF1 and BRLF1, which exhibit simi-dependent upon the activation of an estimated 100 or
lar induction kinetics (Takada and Ono, 1989; Flemingtonmore viral genes, culminating in the production of infec-
et al., 1991). The protein products of both the BZLF1 genetious virions (reviewed in Kieff and Liebowitz, 1989; Baer
(referred to here as Zta, but also known as ZEBRA andet al., 1984; Bauer et al., 1982; Hummel and Kieff, 1982;
EB1) and the BRLF1 gene (referred to as Rta) are tran-Cohen et al., 1984). During latency, little or no viral repli-
scriptional activators (Chevallier-Greco et al., 1986;cation takes place. Rather, immortalization of EBV-in-
Countryman and Miller, 1985; Farrell et al., 1989; Groganfected B cells is achieved through the expression of a
et al., 1987; Hardwick et al., 1988; Miller et al., 1984;small subset of viral genes which serve to establish and
Countryman et al., 1987; Urier et al., 1989; Lieberman andmaintain cellular growth transformation (for a review see
Berk, 1990; Chang et al., 1990; Flemington and Speck,Kieff and Liebowitz, 1989). However, a switch in the ge-
1990b,c; Kouzarides et al., 1991; Liberman et al., 1990).netic program leading to the expression of viral replica-
The BZLF1 promoter (Zp) exhibits very low basal activ-tion-associated genes can be accomplished in vitro by
ity, which is potently upregulated by inducers of the viraltreatment of latently infected B cells with various activat-
lytic cycle (Flemington and Speck, 1990a; Daibata et al.,ing agents, including phorbol esters, Ca2/ ionophores,
1994; Borras et al., 1996). The region from 0221 to /12and anti-immunoglobulin antibodies (Kallin et al., 1979;
bp of Zp harbors the necessary cis-elements for main-
taining low basal activity and for transcriptional activation
1 To whom correspondence and reprint requests should be ad- by lytic cycle-inducing agents (Flemington and Speck,dressed at Department of Pathology, Box 8118, 660 S. Euclid Avenue,
1990a; Borras et al., 1996). Within this sequence, threeSt. Louis, MO 63110. Fax: (314) 362-4096. E-mail: speck@pathology.
wustl.edu. distinct types of response elements have been defined
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(see Fig. 1): (i) A / T-rich sequences termed ZI domains, modifications. Cells (107 per transfection) were pelleted
at 1000 g, washed once with sterile phosphate-bufferedfour related copies of which are interspersed in the pro-
moter (ZIA–D); (ii) a unique element, ZII, which shares saline (PBS), and resuspended in 0.25 ml of PBS per
transfection. Cells were added to sterile tubes containinghomology with consensus CREB/AP1 binding sites
(Flemington and Speck, 1990a; Borras et al., 1996; Ruf 2 mg of the appropriate vector in 0.25 ml of DEAE–dex-
tran (1 mg/ml), incubated at room temperature for 20 min,and Rawlins, 1995); and (iii) two adjacent sites, termed
ZIIIA and ZIIIB, which bind the BZLF1 gene product Zta and subjected to dimethyl sulfoxide shock (final concen-
tration of 7%) for 2 min. Each tube was washed with 10(Flemington and Speck, 1990b). ZIIIA, but not ZIIIB, is an
AP1 response element (Flemington and Speck, 1990b). ml of PBS, resuspended in 10 ml of complete medium,
and cultured at 377 in a 5% CO2 incubator. For TPA induc-Induction of the BZLF1 gene appears to involve two
steps: (i) initial activation of the promoter by inducers of tion, duplicate samples were transfected together in the
same tube and following transfection split into two cul-the lytic cycle, mediated through the ZI and ZII domains,
which results in low-level transcription of the BZLF1 tures resuspended in complete media { TPA. Final TPA
concentration was 20 ng/ml.gene; followed by (ii) autoactivation of Zp mediated
through Zta binding to the ZIIIA and ZIIIB domains. We Cells were harvested 72 hr posttransfection by centrif-
ugation at 1000 g, washed once in PBS, and resus-have previously shown that Zta autoactivation of Zp
strongly synergizes with induction through the ZI and ZII pended in 100 ml of 0.25 M Tris–chloride, pH 7.5. The
samples were lysed by three consecutive rounds ofdomains (e.g., triggered by phorbol esters) (Flemington
and Speck, 1990b; Borras et al., 1996). Thus, we have freeze-thawing, and the cellular debris was removed by
centrifugation in a microcentrifuge at maximal speed.proposed that the duration and magnitude of the initial
signal may determine whether enough Zta is generated Eighty percent of the supernatant was used in CAT
assays as previously described (Gorman et al., 1982).in an appropriate time interval to trigger the entire lytic
cascade. The extent of acetylation was determined by exposure
to a PhosphoImager plate (Molecular Dynamics).We have recently reported a detailed analysis of the
role of the ZIA and ZIC domains in TPA inducibility of Zp
Construction of vectors(Borras et al., 1996). Both domains exhibit phorbol ester
inducibility when multimerized upstream of a minimal The heterologous [3 1 ZI][ZII] constructs were cloned
into BGCAT (Borras et al., 1996), which has the minimalpromoter. Phorbol ester inducibility was greatly aug-
mented by inclusion of a single copy of the ZII domain, b-globin promoter upstream of the CAT reporter gene in
the pGL2 vector. This minimal b-globin promoter con-which on its own exhibited little activity. This suggested
that TPA induction of Zp requires cooperation between tains a 37-bp sequence with the TATA box and down-
stream sequences through the site of transcription initia-cellular factors bound to the ZI and ZII domains. Analysis
of cellular factor binding to the ZI sites revealed several tion. Double-stranded oligonucleotides containing the
three copies of a ZI element were then cloned into thecomplexes which could be resolved on nondenaturing
polyacrylamide gels. Methylation interference analyses AvaI/XbaI restriction sites upstream of the b-globin TATA
box. A single copy of the ZII element was cloned into theof these complexes demonstrated that the slowest mi-
grating complex (complex 1) was centered over the re- XbaI/BamHI sites. The sequences of the sense strand of
the oligonucleotides used for cloning were as follows: 3gion of sequence homology between the ZI domains (Fig.
1B). However, complexes 2, 3, and 4 were shifted slightly 1 ZICwt, 5*-CCGGGACTGCCTCCTCCTCTTTTAGAAAC-
TAACTGCCTCCTCCTCTTTTAGAAACTAACTGCCTCC-upstream of the homology region and exhibited identical
patterns of sensitivity to methylation (Fig. 1B). In this pa- TCCTCTTTTAGAAACTAT-3*; 1 1 ZIIwt, 5*-CTAGACGTC-
CCAAACCATGACATCACAGAGGAG-3*. The mutationsper we demonstrate that complex 2 reflects binding of
Sp1, while complexes 3 and 4 reflect binding of the re- introduced into the ZIC mutants are given in Fig. 4. Oligo-
nucleotides with these base changes were synthesizedlated transcription factor Sp3.
and cloned into the appropriate restriction sites.
The [3 1 Sp1][ZII]bGCAT reporter construct was gen-MATERIALS AND METHODS
erated by cloning a double-stranded oligonucleotide con-
Cell culture, transfections, and chloramphenicol
taining three consensus Sp1 sites into the AvaI/XbaI re-
acetyltransferase (CAT) assays
striction endonuclease sites upstream of the ZII domain
in the previously described [ZII]bGCAT reporter con-The EBV-negative Burkitt’s lymphoma B cell line DG75
was grown at 377 in RPMI 1640 medium (GIBCO Labora- struct (Borras et al., 1996). The sequence of the sense
strand of the oligonucleotide containing three copies oftories) supplemented with 10% fetal calf serum, gluta-
mine, and penicillin–streptomycin (Mediatech). DG75 a consensus Sp1 site was as follows: 5*-CCGGGTCGA-
TCGGGGCGGGGCGAGCTCGATCGGGGCGGGGCGA-cells were transfected using DEAE–dextran as de-
scribed previously (Borras et al., 1996), with the following GCTCGATCGGGGCGGGGCGAGCT-3*.
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Electrophoretic mobility shift assays
DG75 crude nuclear extracts were prepared as de-
scribed previously (Flemington and Speck, 1990a). A total
reaction volume of 20 ml containing 5 mg of extract, 5 ml
of buffer D (20 mM HEPES, pH 7.9, 20% glycerol, 0.1 M
KCl, 0.2 mM EDTA, 0.5 mM PMSF, and 0.5 mM DTT), 4.5
mg of bovine serum albumin, 0.5 ml of 0.1 M DTT, and 2
mg of salmon sperm DNA was incubated at room temper-
ature for 5 min. If competitor oligonucleotides were used,
they were added at this point. The relevant 32P-labeled
double-stranded oligonucleotide (0.4 ng per reaction,
corresponding to 200,000 to 300,000 cpm) was added
and incubated at room temperature for 30 min. Samples
were loaded onto a running nondenaturing 4% acryl-
amide:0.1% bisacrylamide gel. The gel was run in 0.51
TBE (11 TBE is 90 mM Tris, 64.6 mM boric acid, and 2.5
FIG. 1. (A) Organization of cis-elements in the BZLF1 promoter (Zp)
mM EDTA, pH 8.3). The 11 oligonucleotides used were as previously identified by DNase I footprinting in conjunction with
designed to include the entire region protected from functional analyses (Flemington and Speck, 1990a,b). The ZI domains
were functionally grouped together on the basis of sequence similarityDNase I digestion (Flemington and Speck, 1990a). The
and binding competition studies (Flemington and Speck, 1990a). Thesense strands of these oligonucleotides are as follows:
ZII domain contains a consensus cyclic AMP response element-AP1ZIAwt, 5*-CCGGGAACTGGGCTGTCTATTTTTGACACC-
binding site, while the ZIIIA and ZIIIB domains are binding sites for the
AGT-3*; ZICwt, 5*-CTAGAACTGCCTCCTCCTCTTTTA- BZLF1 gene product, Zta, which serves to positively autoregulate Zp
GAAACTATG-3*. The mutations introduced into the ZIC activity (Flemington and Speck, 1990b). (B) Sequence alignment of the
ZI domains present in Zp. The core homology domain is highlighted inelement are shown in Fig. 4. Oligonucleotides with these
the shaded rectangle, while the regions identified as being involvedbase changes were synthesized and used in the assay.
in binding cellular transcription factors, as previously determined by
methylation interference (Borras et al., 1996), are indicated above. The
RESULTS AND DISCUSSION ability to form complexes 1, 2, 3, or 4 for individual ZI domains is
indicated to the right of the ZI sequences. (C) Sequence homologyInspection of the region of the ZIC domain involved in
between the Sp1 consensus sequence and Sp1 binding sites present
binding complexes 2, 3, and 4 revealed homology to a in the epidermal growth factor receptor (Johnson et al., 1988) are shown
CCT repeat motif present in the promoter for the epider- aligned with the core sequences in the ZIA and ZIC domains involved
in binding complexes 2, 3, and 4.mal growth factor (EGF) receptor gene (Johnson et al.,
1988). In the EGF receptor gene promoter two copies of
this element are present, and it has been demonstrated
sults strongly argue that complex 2 represents bindingthat one of the factors that binds specifically to these
of Sp1 to the ZIC domain.elements is the ubiquitous cellular transcription factor
Based on the similarities in binding of complexes 2,Sp1 (Johnson et al., 1988). A comparison of the se-
3, and 4 to the ZIC element (Borras et al., 1996), wequences involved in binding Sp1 in the EGF receptor
considered the possibility that other Sp1 family memberspromoter to the Sp1 consensus binding site is shown in
might also bind to this cis-element. Sp3 is a family mem-Fig. 1C (note that the sequences for ZIC and ZIA shown
ber which has been shown to repress transcriptionalin Fig. 1C are the inverse complement of that shown in
activation by Sp1 (Hagen et al., 1994). Thus, Sp3 bindingFig. 1B).
to ZI domains might be involved in diminishing basalBased on the homology between the ZIC domain and
activity of Zp by blocking Sp1 binding. To address thisthe EGF receptor promoter Sp1 binding sites, we as-
possibility, antibodies which specifically recognize Sp3sessed Sp1 binding to a double-stranded oligonucleotide
(Hagen et al., 1994) were added to the ZIC EMSA reac-probe containing the ZIC domain (Fig. 2). As shown in
tion. As shown in the righthand panel of Fig. 2A, anti-Fig. 2A, addition of an antibody directed against Sp1 to
Sp3 antibodies specifically blocked the formation of com-the EMSA assay resulted in the disappearance of com-
plexes 3 and 4. It has previously been shown that thisplex 2 and the appearance of a weak supershift. Further-
antibody reagent blocks Sp3 binding and does not givemore, when purified Sp1 was used a complex was ob-
rise to a shifted complex(es) (Hagen et al., 1994). In addi-served with similar mobility to complex 2 (Fig. 2A). Addi-
tion, the presence of two shifted complexes that reacttion of anti-Sp1 antibodies to the EMSA with purified
with the anti-Sp3 antibody has previously been observedSp1 resulted in a supershifted band which migrated with
(Hagen et al., 1994). The faster migrating species (com-similar mobility to the shifted complex observed with
crude nuclear extract (Fig. 2A). Taken together these re- plex 4) may reflect binding of a smaller species of Sp3
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to that observed with the ZIC probe, further substantiating
the identification of Sp1 and Sp3 as the factors binding
to ZIC. In addition, anti-Sp1 antibodies specifically super-
shifted the slowest migrating complex (complex 2; see
Fig. 2B).
Based on our previous characterization of cellular fac-
tor binding to the other ZI domains, it is apparent that
both the ZIA and the ZID domains also form complexes
2, 3, and 4 (Borras et al., 1996). That these complexes
represent binding of the same cellular factors was estab-
lished by binding competitions between the various ZI
domains (Borras et al., 1996). To confirm that Sp1 does
indeed bind to the ZIA domain, anti-Sp1 antibody was
added to the ZIA EMSA reaction (Fig. 3). As expected,
anti-Sp1 blocked binding of complex 2, but did not signifi-
cantly affect the binding of complexes 1, 3, or 4 (note,
no supershift of complex 2 was apparent under these
assay conditions). Antibodies which specifically recog-
FIG. 2. (A) Sp1 and Sp3 bind to the ZIC domain. Electrophoretic nize the cellular transcription factors YY1 or c-myc were
mobility shift analyses (EMSAs) of the ZIC domain with crude nuclear employed as negative controls and failed to alter the
extract prepared from the EBV-negative Burkitt’s lymphoma cell line
observed EMSA pattern. In addition, binding of cellularDG75 (prepared as previously described in Borras et al., 1996) or with
factors to the ZIB domain (which does not exhibit forma-purified Sp1 protein (Promega) were carried out under standard assay
conditions (Borras et al., 1996). The ZIC probe employed has been tion of complexes 2, 3, or 4) was unaffected by addition
previously described (Borras et al., 1996). The specific complexes are of anti-Sp1 antibodies (Fig. 3, righthand panel).
indicated to the left of the gel and correspond to those indicated in Our previous analysis of the nucleotides whose meth-
Fig. 1B. Antibodies specific for either Sp1 (Santa Cruz Biotechnologies)
ylation blocked cellular factor binding to the ZIC domainor Sp3 (Hagen et al., 1994) were added as indicated. (B) Probes con-
indicated that the purine stretch on the antisense strandtaining either the ZIC domain or a consensus Sp1 site exhibit the same
pattern on EMSA gels which can be competed by either the ZIC or the is involved in binding these factors (Borras et al., 1996).
Sp1 probes. EMSAs employed either the ZIC probe described in A or In addition, mutating blocks of three nucleotides across
a probe containing a consensus Sp1 site (Promega), employing crude this region was shown to abrogate formation of com-
nuclear extract prepared from DG75 cells. The specific complexes
plexes 2, 3, and 4 (Borras et al., 1996). To further investi-formed are indicated to the left of the gel. Various amounts of unlabeled
gate Sp1 and Sp3 binding to this region of ZIC, severalcompetitor oligonucleotide were added to the EMSA binding reaction
as indicated. Supershift of the slowest migrating complex formed with additional mutants were generated (Fig. 4A). Binding to
the Sp1 probe with anti-Sp1 antibodies is also shown, carried out as these mutants was assessed as shown in Fig. 4B, and
described in A.
that arises from translation initiation at an internal AUG
codon (G.S., unpublished data). The basis for the varia-
tion in the relative abundance of complexes 3 and 4 with
different nuclear extract preparations is unclear (com-
pare left and right panels in Fig. 2A).
To further characterize Sp1 and Sp3 binding to the ZIC
element, competition with an unlabeled double-stranded
oligonucleotide containing a consensus Sp1 binding site
was carried out (Fig. 2B). This analysis clearly demon-
strated that the Sp1 probe could readily compete for
complexes 2, 3, and 4 (complete competition with only
15 ng of competitor). When the Sp1 probe was labeled FIG. 3. Demonstration of Sp1 binding to the ZIA domain, but not the
and unlabeled ZIC double-stranded oligonucleotide was ZIB domain. EMSAs were carried out employing DG75 crude nuclear
extract as described in Fig. 2. The specific complexes described inused as a competitor, ZIC was able to compete for bind-
Fig. 1B are indicated to the left of the EMSA gels. The indicated specificing but much less efficiently than the Sp1 oligonucleo-
antibodies were added to the EMSA binding reaction prior to additiontide. This clearly indicates that the affinity of Sp1 and
of labeled probe as described in the legend to Fig. 2. Control supershifts
Sp3 for the ZIC domain is much lower than for a consen- were performed employing specific antibodies to the cellular transcrip-
sus Sp1 binding site. It should be noted that the pattern tion factors c-myc (Santa Cruz Biotechnologies) and YY1 (Santa Cruz
Biotechnologies).of cellular factor binding to the Sp1 probe was identical
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viously showed, mutation of the first CCT repeat to AGG
strongly diminished Sp1 and Sp3 binding (Borras et al.,
1996). However, surprisingly, mutation of the first CCT to
GGA resulted in a strong induction of binding (see m2
mutant; Figs. 4B and 4C). Subsequent dissection of this
mutation revealed that changing the first C to a G gave
rise to a nearly sevenfold increase in the level of Sp1
and Sp3 binding, while mutation of the second C to a G
or mutation of the T to an A strongly inhibited binding
activity (see m2a, m2b, and m2c mutations; Figs. 4B and
4C). Notably, introduction of the identical mutation into
the second CCT repeat resulted only in a strong inhibition
of binding. This is consistent with our previous observa-
tion with another mutation introduced into this region
(Borras et al., 1996). An analogous dissection of this mu-
tation failed to reveal any mutation which enhanced bind-
ing, although mutating the T to an A only modestly re-
duced binding of Sp1 and Sp3 (see mutation m3c; Figs.
4B and 4C). Thus based on this analysis, along with
our previous mutagenesis, all three CCT repeats appear
important for binding Sp1 and Sp3. Furthermore, as evi-
denced by mutation of the C immediately downstream of
the CCT repeat to a G, nucleotides outside the CCT re-
peat also strongly affected binding (see mutations m4
and m5; Figs. 4B and 4C). These mutations lie within the
region previously demonstrated by methylation interfer-
ence to be involved in binding complexes 2, 3, and 4
(shown here to be Sp1 and Sp3) (Borras et al., 1996).
The only mutation that affects binding that lies outside
the region identified by methylation interference is the
m5 mutation we previously reported (Borras et al., 1996),
which mutates the region immediately downstream of
the region protected from methylation. A slightly more
distal mutation (m6), which also lies outside the region
FIG. 4. Sequences of ZIC probes containing specific mutations and protected in the methylation interference assays, did not
summary of Sp1 and Sp3 binding. Sequences within the open rectangle affect binding of Sp1 and Sp3 (Figs. 4B and 4C). Taken
are within the region previously demonstrated by methylation interfer- together, these results indicate that the affinity of Sp1ence to be involved in contacting the cellular transcription factors pres-
and Sp3 for the ZIC domain is strongly affected by criti-ent in complexes 2, 3, and 4 (Borras et al., 1996). Those ZIC mutants
cally placed G and C residues within the binding site.within the brackets were previously characterized for binding (Borras
et al., 1996) and are shown for comparison. (B) Analysis of specific This notion is most strongly supported by the ca. sev-
mutations on Sp1 and Sp3 binding to the ZIC domain. EMSAs were enfold enhancement in binding observed with the m2a
carried out with DG75 crude nuclear extract as described in the legend mutation, in which a single C was changed to a G.to Fig. 2. The specific complexes are indicated to the left of the EMSA
To assess whether Sp1/Sp3 binding could account forgel and are those depicted in Fig. 1B. (C) Quantitation of Sp1 and Sp3
the functional behavior displayed by heterologous re-binding to ZIC mutants. The EMSA analysis shown in B was quantitated
employing a Phosphorimager (Molecular Dynamics). The level of bind- porter constructs containing ZIC sites, we generated a
ing for each mutant is shown relative to the binding observed with the heterologous promoter containing three consensus Sp1
unmutated ZIC probe (wt), which was assigned a value of 1.0. sites linked to a single copy of the ZII domain from Zp
cloned upstream of a minimal b-globin promoter driving
expression of the CAT reporter gene ([3 1 Sp1][ZII]-the EMSA results were quantitated on a PhosphorImager
(Molecular Dynamics). Mutation of the three nucleotides bGCAT). This is analogous to reporter constructs that
we previously characterized that contain three copies ofimmediately upstream of the CCTCCTCCT motif de-
creased binding ca. threefold. It should be noted that the individual ZI domains cloned upstream of the ZII domain
in the b-globin promoter CAT vector (Borras et al., 1996).last nucleotide in the triplet was previously determined
by methylation interference to be a contact residue for TPA and ionomycin inducibility of the [3 1 ZIC][ZII]-
bGCAT and [3 1 Sp1][ZII]bGCAT reporter constructsSp1 and Sp3 binding (Borras et al., 1996). As we pre-
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FIG. 5. Correlation between Sp1 binding and TPA inducibility of heterologous promoters. (A) A heterologous promoter containing multiple Sp1
sites exhibits phorbol ester inducibility. DG75 cells were transiently transfected with 2 mg of the indicated reporter construct by the DEAE–dextran/
DMSO shock protocol, as previously described (Borras et al., 1996). Generation of the indicated heterologous promoter constructs is described
under Materials and Methods. TPA (20 ng/ml final concentration) and ionomycin (1 mM final concentration) were added immediately posttransfection
as indicated. Transfected cells were harvested 72 hr posttransfection and analyzed for CAT activity as previously described (Borras et al., 1996).
Activities are expressed relative to the activity observed with the [3 1 ZIC][ZII]bGCAT reporter construct in the presence of TPA and ionomycin
(defined as an activity of 1.0). Compiled data from three independent transfections is shown. (B) ZIC mutants with altered Sp1 binding exhibit altered
basal and TPA-inducible activities. The mutations introducted into the ZIC domain are shown in Fig. 4A. Reporter constructs were transfected into
DG75 cells, and CAT activity was assessed as described in A and under Materials and Methods.
was compared (Fig. 5A). As previously observed with the shown to interfere with Sp1-mediated transcriptional acti-
vation (Hagen et al., 1994), this might also lead to low-[3 1 ZIC][ZII]bGCAT reporter construct (Borras et al.,
1996), addition of TPA induced CAT activity. Ionomycin ering basal activity.
To further address the question of whether affinity ofhad little effect, and the combination of TPA and iono-
mycin enhanced activity less than twofold over that ob- Sp1/Sp3 binding correlates with observed basal activity,
we generated [3 1 ZIC][ZII]bGCAT reporter constructsserved with TPA alone. Notably, the [3 1 Sp1][ZII]bGCAT
reporter construct exhibited significantly higher basal ac- in which the m2, m2a, or m2b mutations (see Fig. 4A)
were introduced into all three copies of the ZIC element.tivity than the [3 1 ZIC][ZII]bGCAT reporter construct
(see Fig. 5A). However, as observed with the [3 1 As shown in Fig. 4B, the m2 and m2a mutations in-
creased the affinity of Sp1 and Sp3 for the ZIC element,ZIC][ZII]bGCAT reporter construct, the [3 1 Sp1][ZII]-
bGCAT reporter construct exhibited TPA inducibility while the m2b mutation disrupted binding of Sp1 and
Sp3 to the ZIC element. When these reporter constructswhich could be slightly augmented by the addition of
ionomycin (Fig. 5A). It should be noted that we have were assayed in the DG75 cell line, both the m2 and the
m2a mutants exhibited increased basal and TPA-inducedpreviously demonstrated that heterologous promoter
constructs containing only a single copy of the ZII domain activities compared to that of the unmutated promoter
(Fig. 5B). However, the m2b mutation significantly dimin-cloned upstream of the minimal b-globin promoter exhib-
ited little or no TPA inducibility (Borras et al., 1996). ished both basal and induced activity (Fig. 5B). These
results are consistent with the hypothesis that higherOverall, the functional characteristics of the [3 1
ZIC][ZII]bGCAT and [3 1 Sp1][ZII]bGCAT reporter con- affinity Sp1/Sp3 binding leads to an increase in basal
activity. Furthermore, the effect of the point mutation in-structs are similar. The higher basal activity exhibited by
the [3 1 Sp1][ZII]bGCAT reporter construct correlates troduced in the ZICm2b reporter construct provides a
strong correlation between decreased affinity of Sp1/Sp3with the higher affinity binding of Sp1 and Sp3 for the
consensus Sp1 site compared to the ZIC site (see Fig. binding and loss of activity.
In the case of the ZIC domain, Sp1 and Sp3 are the2B). As such, in vivo occupancy of the ZI sites by Sp1
(or Sp3) would be expected to be less than that of sites only cellular factors we have detected binding to this
site. However, for the ZIA and ZID domains, in additionthat more closely match the consensus Sp1 recognition
sequence, thereby leading to lower constitutive activity. to Sp1 and Sp3 binding, there is clearly another cellular
factor involved in binding to these cis-elements (BorrasIn addition, although there is no evidence from our bind-
ing analyses, it is possible that under physiological con- et al., 1996), which we have recently identified as MEF2D
(a member of the myocyte enhancer factor 2 family, alsoditions the balance between Sp1 and Sp3 binding may
be different between these sites. Since Sp3 has been known as related to serum response factor family) (Liu
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Cohen, L. K., Speck, S. H., Roberts, B. E., and Strominger, J. L. (1984).et al., 1996). MEF2D binds to the region of highest homol-
Identification and mapping of polypeptides encoded by the P3HR-1ogy between the ZI domains (see Fig. 1), while the region
strain of Epstein–Barr virus. Proc. Natl. Acad. Sci. USA 81, 4183–
binding Sp1/Sp3 is shifted slightly upstream (Borras et 4187.
al., 1996; Liu et al., 1996). Given the extensive overlap Countryman, J., and Miller, G. (1985). Activation of expression of latent
Epstein–Barr herpesvirus after gene transfer with a small clonedbetween these binding sites, it is very unlikely that both
subfragment of heterogeneous viral DNA. Proc. Natl. Acad. Sci. USAMEF2D and Sp1/Sp3 could bind simultaneously to a sin-
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